21 completed, 4 recruiting, 2 terminated, 2 unknown. 30 Phase 1, 9 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 30 | Completed 21, Recruiting 4, Terminated 2, Unknown 2, Active not recruiting 1 |
| Phase 2 | 9 | Completed 4, Recruiting 3, Active not recruiting 1, Terminated 1 |
Follow Myelitis: new trials by email Literature Review of Myelitis trials Research Report on Myelitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase I/II Clinical Trial of the Diphtheria, Tetanus, Acellular Component Pertussis and Sabin Inactivated Poliomyelitis Vaccine Adsorbed Diphtheria, Tetanus, Acellular Component Pertussis and Sabin Inactivated Poliomyelitis Vaccine Adsorbed, Diphtheria, Tetanus and Acellular Component Pertussis Combined Vaccine, Diphtheria, Tetanus and Acellular Component Pertussis Combined Vaccine+Inactivated Poliomyelitis Vaccine Made From Sabin Strains - Diphtheria, Pertussis | Phase 1 / Phase 2 | Recruiting | Institute of Medical Biology, Chinese Academy of Medical Sciences | 380 | 2026-10-11 | 2026-10-23 |
| Safety and Immunogenicity of a Recombinant Poliomyelitis Vaccine (rPV) in Comparison With IPOL Vaccine in Healthy Adults Recombinant Poliomyelitis Vaccine (rPV), Inactivated Poliomyelitis Vaccine (IPOL) - Polio Immunity | Phase 1 | Recruiting | Serum Institute of India Pvt. Ltd. | 36 | 2026-09-11 | 2026-09-29 |
| A Study to Evaluate the Safety and Immunogenicity of VLP-Polio in Infants and Toddlers Recombinant Trivalent Poliomyelitis Vaccine (Sf-RVN Cell) (VLP-Polio) low adjuvant dose, VLP-Polio medium dose, VLP-Polio high dose - Poliomyelitis | Phase 1 / Phase 2 | Active not recruiting | CanSino Biologics Inc. | 480 | 2024-12-19 | 2026-08-06 |
| Study of Trivalent and Bivalent (Types 1 & 2) Novel Oral Poliomyelitis Vaccines Novel oral poliomyelitis vaccine type 1 (nOPV1), Novel oral poliomyelitis vaccine type 2 (nOPV2), Novel oral poliomyelitis vaccine type 3 (nOPV3) - Poliomyelitis | Phase 1 / Phase 2 | Recruiting | PATH | 2400 | 2024-11-20 | 2025-06-03 |
| A Study to Evaluate the Safety and Immunogenicity of Recombinant Trivalent Poliomyelitis Vaccine (Sf-RVN Cell) in Healthy Adults Recombinant Trivalent Poliomyelitis Vaccine (Sf-RVN Cell) (VLP-Polio), Inactivated poliomyelitis vaccine (IPOL), VLP-Polio - Poliomyelitis | Phase 1 | Completed | CanSino Biologics Inc. | 72 | 2024-01-15 | 2024-12-04 |
| A Study to Evaluate Safety and Immunogenicity of APV006 in Healthy Adults DTaP-HepB-IPV-Hib vaccine - Diphtheria, Tetanus | Phase 1 | Unknown | LG Chem | 42 | 2023-07-17 | 2023-07-19 |
| Study to Investigate the Safety of the Transplantation of Human Glial Restricted Progenitor Cells Into Subjects With Transverse Myelitis Q-Cells - Transverse Myelitis | Phase 1 / Phase 2 | Recruiting | Q Therapeutics, Inc. | 9 | 2022-09-20 | 2026-07-21 |
| A Clinical Pharmacological Study of MT-3921 in Subjects With HTLV-1 Associated Myelopathy (HAM) MT-3921, Placebo - HTLV-1-Associated Myelopathy (HAM) | Phase 1 | Completed | Tanabe Pharma Corporation | 15 | 2022-05-02 | 2024-01-29 |
| Intradermal Fractional Dose IPV (fIPV) in Combination With dmLT Intradermal fractional dose inactivated polio vaccine (fIPV) in combination with recombinant double mutant heat labile toxin, LT(R192G/L211A), (dmLT), Intradermal fractional dose inactivated polio vaccine (fIPV), Monovalent oral poliomyelitis vaccine (mOPV), Sabin strain - Poliomyelitis | Phase 1 | Unknown | University of Vermont | 19 | 2022-04-01 | 2023-11-29 |
| Study of Novel Types 1 and 3 Oral Poliomyelitis Vaccines Novel Oral Polio Vaccine Type 1 (nOPV1), Novel Oral Polio Vaccine Type 3 (nOPV3), Sabin Monovalent Oral Polio Vaccine Type 1 (mOPV1) - Poliomyelitis | Phase 1 | Completed | PATH | 226 | 2021-03-26 | 2024-11-20 |
| Inactivated Poliovirus Vaccine (IPV) With or Without E.Coli Double Mutant Heat-Labile Toxin (dmLT) Challenge Study in Healthy Adults Inactivated Poliomyelitis Vaccine (IPV), E.coli Double Mutant Heat-Labile Toxin (dmLT) (adjuvant), Bivalent Oral Polio Vaccine (bOPV) - Polio | Phase 1 | Completed | PATH | 87 | 2020-01-22 | 2022-09-06 |
| Evaluation of Safety, Reactogenicity and Immunogenicity of Fractional-dose Inactivated Polio Vaccine (fIPV) Given Intradermally With Double Mutant Enterotoxigenic Escherichia Coli Heat Labile Toxin (dmLT) Adjuvant dmLT, fIPV - Polio | Phase 1 | Completed | University of Vermont | 29 | 2019-03-19 | 2020-08-05 |
| Safety and Immunogenicity of a Sabin Inactivated Poliovirus Vaccine (Phase Ib) sIPV - Polio | Phase 1 / Phase 2 | Completed | Jiangsu Province Centers for Disease Control and Prevention | 60 | 2017-11-24 | 2020-02-11 |
| Safety and Immunogenicity of a Sabin Inactivated Poliovirus Vaccine sIPV, Commercialized sIPV, Commercialized IPV - Polio | Phase 1 | Completed | Jiangsu Province Centers for Disease Control and Prevention | 100 | 2017-08-21 | 2020-02-11 |
| Central Pain Study for ABX-1431 ABX-1431 HCl, Placebo - Neuromyelitis Optica Spectrum Disorder, Transverse Myelitis | Phase 1 | Completed | Abide Therapeutics | 9 | 2017-08-01 | 2019-01-25 |
| A Study to Compare LBVD to Eupenta and Imovax Polio in Healthy Adults DTP-HepB-IPV-Hib vaccine, DTP-HepB-Hib vaccine & IPV - Diphtheria, Tetanus | Phase 1 | Completed | LG Chem | 42 | 2017-07-03 | 2019-08-29 |
| IPV-102 Safety, Tolerability and Immunogenicity of TAK-195 in Healthy Infants, Toddlers and Adults Sabin-Based Inactivated Poliomyelitis Vaccine (sIPV), Reference IPV, sIPV Placebo - Poliomyelitis | Phase 1 / Phase 2 | Terminated | Takeda | 340 | 2017-06-07 | 2020-01-31 |
| Phase 1 Novel Live Attenuated Serotype 2 Oral Polio Vaccine Study in Inactivated Polio Vaccine (IPV) Primed Adults Novel OPV2 candidate 1, Novel OPV2 candidate 2 - Poliomyelitis | Phase 1 | Completed | Pierre Van Damme | 30 | 2017-05-16 | 2021-02-04 |
| Studies of the Safety and Immunogenicity of a Sabin Inactivated Poliovirus Vaccine Single-dose regimen of high dosage investigational sIPV, Single-dose regimen of medium dosage investigational sIPV, Three-dose regimen of high dosage investigational sIPV - Poliomyelitis | Phase 1 / Phase 2 | Completed | Sinovac Biotech Co., Ltd | 708 | 2016-10-01 | 2017-07-26 |
| Ublituximab for Acute Neuromyelitis Optica (NMO) Relapses Ublituximab - Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder | Phase 1 | Completed | Johns Hopkins University | 6 | 2016-01-01 | 2019-06-06 |
Showing 20 of 30. Sign in to see all of them.
Poliomyelitis (22) · Myelitis, Transverse (4) · Diphtheria (3) · Neuromyelitis Optica (3) · Tetanus (3) · Whooping Cough (3) · Haemophilus Infections (2) · Hepatitis B (2) · Multiple Sclerosis (2) · Paraparesis, Tropical Spastic (2) · Encephalitis (1) · Multiple Sclerosis, Chronic Progressive (1) · Multiple Sclerosis, Relapsing-Remitting (1) · Optic Neuritis (1)
Central Nervous System Diseases (30) · Central Nervous System Infections (30) · Infections (30) · Nervous System Diseases (30) · Neuroinflammatory Diseases (30) · Spinal Cord Diseases (30) · RNA Virus Infections (24) · Virus Diseases (24) · Enterovirus Infections (22) · Neuromuscular Diseases (22) · Picornaviridae Infections (22) · Autoimmune Diseases (5) · Autoimmune Diseases of the Nervous System (5) · Demyelinating Autoimmune Diseases, CNS (5)
Poliovirus Vaccine, Inactivated (7) · Adjuvants, Pharmaceutic (1) · Aging (1) · Hu-Mik-beta-1 monoclonal antibody (1) · LFB-R603 (1) · Rituximab (1) · Tetanus Toxoid (1) · ublituximab (1)
PATH (3) · CanSino Biologics Inc. (2) · Jiangsu Province Centers for Disease Control and Prevention (2) · LG Chem (2) · Pauline Verdijk (2) · University of Vermont (2) · Abide Therapeutics (1) · American CryoStem Corporation (1) · Chinese Academy of Medical Sciences (1) · GlaxoSmithKline (1) · Institute of Medical Biology, Chinese Academy of Medical Sciences (1) · International Vaccine Institute (1) · Johns Hopkins University (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · National Institute of Neurological Disorders and Stroke (NINDS) (1)
United States (8) · China (6) · Belgium (3) · Australia (2) · Poland (2) · Bangladesh (1) · Canada (1) · Cayman Islands (1) · India (1) · Indonesia (1) · Japan (1) · Panama (1) · South Korea (1) · United Kingdom (1)
Beth Kirkpatrick, M.D. (2) · Fengcai Zhu, Master (2) · Pauline Verdijk, PhD (2) · Anu Jacob, MD DM FRCP (1) · Arlene Sena, MD (1) · Ayan Dey, Ph.D (1) · Benjamin Greenberg, MD (1) · Bruce Cree, MD, PhD (1) · Christina Chang, Dr (1) · Dr Hitt Sharma, MBBS MBA (1) · Geert Leroux-Roels, MD, PhD (1) · Jacqueline Palace, FRCP DM (1) · Jessica Crothers, MD (1)
PMID 32867698, PMID 24063976, PMID 25043278, PMID 26873055, PMID 28194449, PMID 30249424, PMID 31174831, PMID 35367069, PMID 36746739, PMID 38218668, PMID 40818478
2017 (1), 2019 (1)